Bong Koh

Bong obtained his MBA from the Harvard Business School, where he did extensive work studying life science entrepreneurship and venture capital. He obtained his MD, with Honors, from the University of California San Francisco and his BA, cum laude, and with Distinction, in biology from Yale University.

Bong joined the healthcare investing team at Venrock in New York 2011 and has been doing public and private investing since 2004. Bong is a manager of Venrock's public and cross-over biotech fund, Venrock Healthcare Partners, where he provides leadership in biotech investments. On the private side, Bong led Avalanche Biotechnologies' (NASDAQ: AAVL) Series B financing and REGENXBIO's series A round; furthermore he led Venrock's Series A investment in Juno Therapeutics (NASDAQ: JUNO) and its Series B investment in Audentes Therapeutics. 

​

In 2006 Bong co-founded and served as Managing Director of Pytho Partners, a fundamental, research-oriented investment firm focused on investing and helping to nurture biotechnology companies in the development phase. Earlier, Bong was a Principal at TVM Capital focusing on private and public clinical-stage companies, where his responsibilities included developing theses and strategies for investing in small-cap biotech companies. 

​

Prior to his career in venture, Bong completed his ophthalmology residency at Harvard Medical School (Massachusetts Eye & Ear Infirmary) and his internal medicine training at Stanford Medical School. He also completed two years of clinical research at Memorial Sloan Kettering Cancer Center under a National Cancer Institute scholarship; at Children's Hospital of Philadelphia under an American Pediatric Society grant; and at UCSF in the department of Pathology.

Bong served his fellowship under mentor Stephen Hoffman at TVM Capital in Boston, MA as a member of Fellows Class 10.